Exagen Inc 's Cash & cash equivalent grew by 14.29 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Exagen Inc 's Quick Ratio to 1.83, Quick Ratio remained below Exagen Inc average.

Within Medical Laboratories industry 17 other companies have achieved higher Quick Ratio than Exagen Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1173 to 1320.

Explain Quick Ratio?
How much Cash & cash equivalents XGN�s has?
What are XGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

XGN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	30.71 %	-10.23 %	23.38 %	67.14 %	22.4 %
Y / Y Cash & cash equivalent Change	-18.13 %	92.18 %	46.22 %	61.8 %	22.69 %
Quick Ratio MRQ	1.83	1.71	2.28	2.77	2.92
XGN's Total Ranking	# 1320	# 1173	# 694	# 845	# 734
Seq. Current Liabilities Change	7.11 %	-11.26 %	9.84 %	25.21 %	-26.44 %
Seq. Cash & cash equivalent Change	14.29 %	-33.23 %	-9.63 %	18.71 %	168.3 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 18
Healthcare Sector	# 515
Overall Market	# 1320

Quick Ratio Statistics
High	Average	Low
14.97	6.3	0.8
(Mar 31 2021)		(Mar 31 2025)

Financial Statements
Exagen Inc 's Current Liabilities	$ 13 Millions	Visit XGN's Balance sheet
Exagen Inc 's Cash & cash equivalent	$ 25 Millions	Visit XGN's Balance sheet
Source of XGN's Sales		Visit XGN's Sales by Geography

Cumulative Exagen Inc 's Quick Ratio

XGN's Quick Ratio for the trailling 12 Months

XGN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	22.06 %	19.99 %	45.12 %	39.71 %	20.45 %
Y / Y Cash & cash equivalent TTM Growth	33.62 %	49.75 %	13.86 %	-10.3 %	-26.9 %
Quick Ratio TTM	2.15	2.39	2.13	2.03	1.96
Total Ranking TTM	# 3846	# 2790	# 2275	# 2930	# 2925
Seq. Current Liabilities TTM Growth	6.34 %	-2.79 %	5.51 %	11.91 %	4.53 %
Seq. Cash & cash equivalent TTM Growth	-4.56 %	9.46 %	10.3 %	15.96 %	6.96 %

Quick ratio ranking by company, industry and sector >> Back to XGN Financial Strength Comparisons >> Go to Compare XGN Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $13.46 millions, cumulative Quick Ratio decreased to 2.15 below the Exagen Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Exagen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2790 to 3846.

Explain Quick Ratio?
How much Cash & cash equivalents XGN�s has?
What are XGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 35
Healthcare Sector	# 880
Within the Market	# 3846

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.02	6.32	1.74
(Dec 31 2021)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions
Radnet Inc	1.11	$ 773.510 Millions	$ 697.822 Millions
Bioaffinity Technologies Inc	0.91	$ 2.430 Millions	$ 2.681 Millions
Ispecimen inc	0.43	$ 4.426 Millions	$ 10.196 Millions
Quest Diagnostics Inc	0.40	$ 720.000 Millions	$ 1,788.000 Millions
Lumexa Imaging Holdings Inc	0.39	$ 69.705 Millions	$ 178.355 Millions

Date modified: 2026-09-26T07:36:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.